Oncology – Medxy AI

Family History Misses Actionable Germline Variants in Many Ovarian Cancer Patients Over 70

By MedXY 05/13/2026

A large real-world registry study shows that ovarian cancer patients aged 70 and older still carry clinically actionable germline variants, often without a reported family history, supporting broader age-inclusive genetic testing.

Diabetes & Endocrinology news Oncology

Most Bilateral Adrenal Lesions Are Benign and Concordant, but Asynchronous Presentation Signals Higher Malignancy Risk

By MedXY 05/13/2026

A large retrospective cohort shows that bilateral adrenal masses are usually benign and concordant, but asynchronous or discordant lesions identify a clinically important subgroup enriched for malignancy and pheochromocytoma.

news Oncology Public Health

Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults

By MedXY 05/12/2026

A population-based study of older adults with metastatic NSCLC found that fewer than half received systemic treatment, with only slight improvement over time. Oncology referral and biomarker testing were strongly linked to treatment, while advanced age and barriers to care lowered access.

news Oncology Public Health

Systemic Treatment Remains Underused in Older Adults With Metastatic Non-Small Cell Lung Cancer

By MedXY 05/12/2026

A large SEER-Medicare study found that fewer than half of older adults with metastatic NSCLC received systemic therapy, with only modest improvement from 2006 to 2021. Specialist referral and biomarker testing were strongly linked to treatment receipt.

Hematology-Oncology news Oncology

Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia

By MedXY 05/11/2026

A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.

Hematology-Oncology news Oncology

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma

By MedXY 05/11/2026

A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.

news OB/GYN & Women’s Health Oncology

Estrogen Therapy Linked to Improved Survival in Certain Ovarian Cancer Patients Under 60

By MedXY 05/11/2026

Study shows post-diagnosis estrogen therapy improves survival in high-grade serous and clear cell ovarian cancers but may worsen outcomes in endometrioid subtypes, offering guidance for managing menopausal symptoms in younger survivors.

Gastroenterology news Oncology

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma

By MedXY 05/10/2026

A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without increasing toxicity.

Gastroenterology news Oncology

A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit

By MedXY 05/10/2026

A large multiomic colorectal cancer study identifies CTHRC1-positive fibroblasts as a stromal biomarker linked to TGF-beta activity, adverse outcomes, and reduced checkpoint inhibitor benefit across both MSI and MSS disease.

Hematology-Oncology news Oncology

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

By MedXY 05/09/2026

A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast cancer.

news Oncology Otorhinolaryngology

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma

By MedXY 05/08/2026

A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.

news Oncology Otorhinolaryngology

Impact of Immunocompromise on Survival in HPV-Positive Throat Cancer Patients

By MedXY 05/08/2026

This study examines how pre-existing immunocompromise affects survival and outcomes in patients with HPV-positive oropharyngeal cancer treated surgically. Immunocompromised patients showed significantly worse overall survival compared to non-immunocompromised peers, underscoring the need for personalized care strategies.

Gastroenterology news Oncology

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer

By MedXY 05/08/2026

Study finds 62% of rectal cancer patients on Watch and Wait receive optimal surveillance, with younger patients showing better adherence. Critical gaps occur in the first year, particularly in initial endoscopic/imaging exams and colonoscopies.

General Surgery news Oncology

Rectal Cancer Accreditation Was Linked to Higher Hospital Volume Without More Care Fragmentation

By MedXY 05/08/2026

A national difference-in-differences study found NAPRC accreditation was associated with modest growth in rectal cancer volume and stage I procedural volume, without evidence of increased care fragmentation.

news OB/GYN & Women’s Health Oncology

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

By MedXY 05/08/2026

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation rates (16%). However, discontinuations often lacked prior dose modification, indicating management optimization opportunities.

Gastroenterology news Oncology

Gut Microbiome Signatures Improve Diagnosis and Prognostic Stratification in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

By MedXY 05/07/2026

A large shotgun metagenomic study links gut dysbiosis to EBV-associated nasopharyngeal carcinoma and shows that microbial markers, especially combined with EBV markers, may strengthen diagnosis and prognostic assessment.

news Oncology Public Health

Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer

By MedXY 05/05/2026

A matched difference-in-differences study found that the Oncology Care Model did not increase systemic therapy initiation overall and was associated with lower treatment initiation and lower spending in poor-prognosis cancers.

Hematology-Oncology news Oncology

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma

By MedXY 05/04/2026

In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell transplantation.

news Oncology Ophthalmology

MBD4 Germline Variants Mark a Strong Predisposition to Uveal Melanoma, Supporting Broad Genetic Screening

By MedXY 05/04/2026

A large French case series found pathogenic or likely pathogenic germline MBD4 variants in 23 of 896 patients with uveal melanoma, corresponding to a 31-fold relative risk versus the general population.

Diabetes & Endocrinology news Oncology

Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent Disease

By MedXY 05/04/2026

In medullary thyroid carcinoma with biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year strongly identified patients at higher recurrence risk and may help tailor surveillance intensity.